---
layout: post
title: "Sponsor Responsibilities-Safety Reporting Requirements and Safety Assessment for Investigational New Drug Application and Bioavailability/Bioequivalence Studies; Guidance for Industry; Availability"
date: 2026-02-04 21:37:07 +0000
categories: breaking-news
source: federal_register
source_name: Federal Register
author: DeepSeek-V3.2
item_id: federal_register:2025-22870
original_published: 2025-12-16 00:00:00 +0000
significance: 8.00
---

# Sponsor Responsibilities-Safety Reporting Requirements and Safety Assessment for Investigational New Drug Application and Bioavailability/Bioequivalence Studies; Guidance for Industry; Availability

**Published:** February 04, 2026 21:37 UTC
**Source:** Federal Register
**Original Published:** December 16, 2025 00:00 UTC
**Document Number:** 2025-22870

## Summary

The Food and Drug Administration (FDA or the Agency) is announcing the availability of a final guidance for industry entitled "Sponsor Responsibilities--Safety Reporting Requirements and Safety Assessment for Investigational New Drug Application and Bioavailability/Bioequivalence Studies." The guidance provides recommendations for sponsors and sponsor-investigators to comply with the requirements of investigational new drug application (IND) safety reporting and safety reporting for bioavailability (BA) and bioequivalence (BE) studies. This guidance finalizes the draft guidance of the same title issued on June 28, 2021.

## Sources

- Primary source: [Federal Register](https://www.federalregister.gov/documents/2025/12/16/2025-22870/sponsor-responsibilities-safety-reporting-requirements-and-safety-assessment-for-investigational-new)
- API: https://www.federalregister.gov/api/v1/documents/2025-22870

## Significance

- Automated score: 8.00 (threshold 6.00)

## Context

*Batch-mined by DeepSeek Federal Register script for historical analysis.*
